Hansa Biopharma AB, ("Hansa" or "the Company"), (Nasdaq Stockholm: HNSA), today announced that the Food and Drug Administration (FDA) ...
29m
Hansa Biopharma AB: PDUFA Action Date for Hansa Biopharma's Imlifidase BLA Set for December 19, 2026
If approved, imlifidase will be the first treatment to address highly sensitized patients awaiting kidney transplantation. LUND, Sweden, March 4, 2026 /PRNewswire/ -- Hansa Biopharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results